Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors

  • ID: 3752114
  • Report
  • Region: Global
  • 1342 Pages
  • La Merie Publishing
1 of 4

FEATURED COMPANIES

  • 3SBio
  • Axxo
  • Dophen Biomed
  • Immune Pharmaceuticals
  • Mundipharm
  • Roche
  • MORE
The Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors, includes the following 4 publications at a 50% discount when purchased altogether as part of a bundle:

- Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis
- T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals
- Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update
- Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

Below are summaries of each report as well as links to purchase the individual titles:

"Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis"

This report describes and analyzes the situation of antibody-drug conjugates as of November 2015 regarding

- ADC pipeline,
- ADC technologies,
- ADC stakeholders and
- ADC business opportunities and commercial perspectives.

Although the initial enthusiasm about antibody-drug conjugates has made room for a more realistic understanding, the prospects for success of ADC drug candidates remain good and are based on a well-filled pipeline, increasing adoption of next generation ADC technologies, lessons learned from failures, a balanced mixture of stakeholders and a variety of options for funding of ADC developments. About 70 ADCs are in clinical and pre-IND stages of development and at least the same number of ADC programs are in preclinical R&D.

For the first time in 2015, combined sales of the approved and marketed ADC products Adcetris and Kadcyla will surpass the sales limit of US$ 1 billion. The pipeline of ADCs and immunoconjugates in advanced clinical development gives the chance of approval of further ADCs in the near- and mid-term future. The clinical attrition rate of ADCs is lower, i.e. better, than that of conventional, naked antibodies in oncology. The availability of next generation ADC technologies allows to select case by case the appropriate linker and payload. Site-specific conjugation technologies with and without engineering of the antibody generate homogenous products. Novel payloads provide the basis for enhanced antitumor activity.

Prodrug concepts and polymeric carrier systems may not only contribute to a higher therapeutic index, but also boost efficacy by targeted delivery of a higher number of payloads than in conventional ADCs. Competition by ADCs directed against the same target is relatively low, except for clinically and commercially validated Her2 which is ideal to validate new technologies. However, targets are still a bottleneck with the attractive consequence that companies with successful target identification capabilities are highly rewarded by investors and business partners.

Nearly all major pharma and biotech companies have ADC programs, although with different strategies of how to gain access to ADC technologies. Few have established proprietary in-house capabilities, most still rely on outside technology providers. However, the duopoly of conventional ADC technology providers is converting into a more differentiated, heterogenous field of ADC technologies and technology providers.

This report entitled „Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis“ is based on the analysis of more than 90 companies, more than 100 ADC drug profiles and more than 26 ADC technologies and components. Sources of information are provided by 274 scientific references and numerous non-scientific references, e.g. press releases, stock exchange disclosures, presentations, annual reports, fact sheets (with hyperlinks leading to source of information). The report also describes and analyzes business deals in the ADC field, e.g. collaboration and license agreements, mergers and acquisitions, financial transactions (divestments, public offerings, private equity and venture capital fund-raising).

Coverage of this ADC report:

- Next-to-market ADCs
- ADC Drug Profiles: clinical, pre-IND, preclinical
- Target Competition by ADCs
- ADC Development Failures
- Conventional & Emerging ADC Technologies
- Polymeric ADC Carriers
- Novel ADC Payloads & Linkers
- Site-specific ADC Conjugation Technologies
- Major Pharma & Biotech Companies with ADC Programs
- Small and Medium Biopharmaceutical Companies with ADC Programs
- Integrated ADC Technology & Pipeline Companies
- Companies with Linker, Payload, Carrier and Conjugation Technologies
- Commercial Opportunities and Perspectives with ADCs
- Commericalization of Approved ADCs
- Fund-Raising for ADC Companies
- Pharma-Biotech & Biotech-Biotech Collaboration & Licensing Agreements

"T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals"

Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR).

Despite stunning clinical results with CD19-targeted CAR T-cells, many major pharmaceutical companies have not embarked on this field of adoptive cell therapy, probably because cell products are a world completely different from that of small molecules or recombinant proteins and antibodies.

Tremendous progress in bispecific antibody technologies during the last decade and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody molecule directed against CD19 lead to an explosion of T-cell redirecting bispecific antibodies in clinical development. Within 18 months, the number of clinical stage T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months.

This report "T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals" as of May 2016 brings you up-to-date information about and analysis of 34 corporate players, 22 key technologies, 47 T-cell and NK-cell redirecting bispecific antibody profiles, business deals and private and public financing rounds.

The report analyzes the pipeline of T-cell and NK-cell redirecting bispecific antibody molecules regarding preferred targets, molecular constructs, dosing schedules, clinical experience, combination study plans, competition with other treatment modalities and the next wave of T-cell and NK-cell redirecting antibodies.

Preferences in bispecific antibody technologies are evaluated regarding drug candidate output, partnering, technological features and impact on clinical administration regimens.

The report highlights the commercial value of T-cell redirecting bispecific antibody immunotherautics in terms of drug prices, sales, company acquisition prices, economic terms of partnering deals, and private or public financing rounds.

All information in the report is fully referenced with 159 scientific references, in many cases with hyperlinks leading to the source of information (abstracts, Posters, papers). Non-scientific references, such as press releases, annual reports or company presentations are disclosed within the text with an embedded hyperlink leading to the online source of information.

What will you find in the report?

- Profiles of 34 companies active in the field;
- Comprehensive description of 23 established and emerging T-cell or NK-cell redirecting antibodies
- Profiles of two approved and 45 T-cell or NK-cell redirecting bispecific antibodies in all phases of development;
- Technology selection and preferences of major pharma;
- Key characteristics of technologies with clinical stage drug candidates
- Emerging alternative bi- and trispecific formats
- Target selection and competition in drug candidates
- Competition of recombinant bispecific molecules with alternative treatment modalities
- Dosing schedules of clinical stage drug candidates based on molecular features
- Economic terms of collaboration and licensing deals;

Who will benefit from the report?

- Venture capital, private equity and investment managers;
- Financial analysts;
- CFO;
- Business development and licensing (BDL) specialists;
- Marketing managers;
- CEO, COO and managing directors;
- Corporate strategy, product and portfolio analysts and managers;
- Chief Technology Officer;
- Cell technology and manufacturing specialists;
- Clinical and preclinical development specialists.

"Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update"

This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target.

The report also describes the next wave of potential biosimilar versions of therapeutic antibodies loosing patent protection in the time frame of 2019 - 2023. The report specifically lists for each target the branded products with their 2015 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.

The report includes a compilation of marketed, approved and currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets relevant for the first wave of biosimilar antibodies (VEGF, TNF, Her2, CD20, EGF-R).

Relevant first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan / MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia, Cyramza, Perjeta, Arrzera are also subject of biosimilar activities.

The report also addresses the slowly emerging second wave of biosimilar antibody activities against originator therapeutic antibodies such as abatacept, alemtuzumab, denosumab, eculizumab, omalizumab, pavilizumab, tocilizumab, and ustekinumab.

Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

"Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases"

This Competitive Intelligence report about Bispecific Antibodies for Cancer, Inflammatory & Other Diseases evaluates the competitive landscape of bispecific therapeutic antibodies for treatment of cancer, anti-inflammatory & autoimmune diseaseas as well as cardiometabolic, infectious, neurologic, ophthalmic and pulmonary diseases as of June 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Tremendous progress in bispecific antibody technologies during the last decade have lead to an explosion of bispecific antibodies in clinical development. This report describes 47 clinical and further 25 pre-IND stage bispecific antibodies in addition to numerous preclinical R&D endeavours. The two specificities provide flexibility in the use as:

- T-Cell or NK cell redirecting bispecific cancer antibodies
- Bispecific immuno-oncology antibodies
- Bispecific tumor antigens targeted cancer antibodies
- Bispecific antibodies for inflammatory & autoimmune diseases
- Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases

The report includes a compilation of currently active projects in development of bispecific therapeutic antibodies including cocktails of antibodies as well as oligo- and polyclonal antibodies. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:

- Drug Codes
- Target / Mechanism of Action
- Class of Compound
- Company
- Product Category
- Indication
- R&D Stage

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3SBio
  • Axxo
  • Dophen Biomed
  • Immune Pharmaceuticals
  • Mundipharm
  • Roche
  • MORE
"Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis"

1 Executive Summary

2 ADC Pipeline Analysis
2.1 Overview
2.2 Next-to-market ADCs
2.3 Next-to-market Immunoconjugates
2.4 ADCs in Early Clinical Development
2.5 ADCs in IND-Enabling Studies
2.6 ADCs in Preclinical R&D
2.7 Competition among ADCs for the Same Target
2.8 Discontinued ADCs and Clinical Attrition Rate

3 ADC Technology Analysis
3.1 Overview
3.2 Conventional and Emerging ADC Technologies
3.3 Probodies and Novel Preclinical Stage Carriers
3.4 Carrier Systems
3.5 Site-Specific Conjugation Technologies with Antibody Engineering
3.6 Site-Specific Conjugation Technologies without Antibody Engineering

4 ADC Stakeholder Analysis
4.1 Major Pharma and Biotech Companies
4.2 Small and Medium Biopharmaceutical Companies
4.3 ADC Technology and Pipeline Companies
4.4 Companies with Novel Payload Technologies
4.5 Companies with Linker, Conjugation & Carrier Technologies
4.6 Companies with Alternative Targeting Moieties

5 ADC Business Analysis
5.1 Overview of Commercial Opportunities and Perspectives with ADCs
5.2 Commercialization of Approved ADCs
5.3 Fund-Raising
5.4 Mergers and Acquisitions
5.5 Pharma – Biotech Collaboration & Licensing Deals
5.6 Biotech – Biotech Collaboration & Licensing Deals

6 ADC Drug Profiles
6.1 Clinical Stage ADC Drug Profiles
6.2 Pre-IND and Preclinical Stage ADC Drug Profiles
6.3 Immunoconjugate Drug Profiles
6.4 Discontinued ADC Drug Profiles

7 ADC Company Profiles
7.1 Major Pharma and Biotech Companies
7.2 Small and Medium Biopharmaceutical Companies
7.3 ADC Technology & Pipeline Companies
7.4 ADC Payload Companies
7.5 ADC Linker, Carrier & Conjugation Technology Companies
7.6 Companies with Alternative Targeting Moieties

8 References

9 ADDENDUM
9.1 Addendum 1: ADCs in Advanced Clinical Development
9.2 Addendum 2: ADCs in Early Clinical Development
9.3 Addendum 3:
9.4 Addendum 4:

10 Tables

Table 1: Overview of Development Stages of ADCs
Table 2: Characteristics of Next-to-Market ADCs in Advanced Clinical Development
Table 3: Next-to-Market Immunoconjugates
Table 4: Characteristics of ADCs in Early Clinical Development
Table 5: Characteristics of ADCs in IND-Enabling Studies
Table 6: Characteristics of ADCs in Preclinical R&D
Table 7: Target Competition of ADCs
Table 8: Overview of ADCs Discontinued from Clinical Development
Table 9: Reasons for failure of ADCs compared with naked antibodies
Table 10: Number of ADC Molecules in Development at Major Pharma & Biotech
Table 11: Targets of Clinical Stage ADC Molecules in Development at Major Pharma & Biotech
Table 12: Technology Licenses for ADCs by Major Pharma & Biotech
Table 13: New ADC Technology Partners of Big Pharma Companies
Table 14: Number of ADC Molecules in Development at Small & Medium Biopharmaceutical Companies
Table 15: Targets and Origin of ADCs at Small & Medium Biopharma
Table 16: Novel ADC Technology In-Licensed by Biopharma Companies
Table 17: Technology Used in ADC Molecules in Development at ADC Technology Companies
Table 18: Number of ADC Molecules in Development at ADC Technology Companies
Table 19: Targets of ADC Molecules in Development at ADC Technology Companies
Table 20: Companies with Novel Payload Technologies
Table 21: Overview of Companies with Linker, Carrier & Conjugation Technologies
Table 22: Companies with Linker, Carrier & Conjugation Technologies
Table 23: Companies with Alternative Targeting Moieties
Table 24: Fund-Raising by ADC Technology and Product Companies in 2014 and 2015
Table 25: Agreements between pharma and biotech companies for ADCs 2014-2015
Table 26: Agreements between biotech and biotech companies for ADCs 2014-2015
Table 27: Clinical Studies with ABT-414
Table 28: Sales of Adcetris
Table 29: Phase III Clinical Studies with Adcetris
Table 30: Actively Recruiting Phase II Clinical Studies with Adcetris
Table 31: Clinical Studies with CDX-011
Table 32: Clinical Study Program of BT062
Table 33: Advanced Phase Clinical Studies with Kadcyla
Table 34: Phase Ib/II Studies with Polatuzumab Vedotin
Table 35: Interim phase II efficacy results of IMMU-132
Table 36: AbbVie’s ADC Pipeline
Table 37: Amgen’s Clinical ADC Pipeline
Table 38: Astellas Pharma’s ADC Pipeline
Table 39: AstraZeneca’s Pipeline of PBD and Tubulysin ADCs
Table 40: Bayer’s ADC Pipeline
Table 41: Novartis ADC Pipeline
Table 42: Pfizer’s Clinical Stage ADC Pipeline
Table 43: Roche Pipeline of Clinical Stage ADCs
Table 44: Roche ADCs Discontinued from Clinical Development
Table 45: Sanofi Clinical Stage ADC Pipeline
Table 46: ADC Pipeline of ADC Therapeutics
Table 47: Asana Biosciences‘ ADC Pipeline
Table 48: ADC Pipeline of Celldex Therapeutics
Table 49: Genmab‘ ADCs in development
Table 50: ADC Pipeline of Oxford BioTherapeutics
Table 51: Preclinical ADC Pipeline of Oxis Biotech
Table 52: Ambrx‘ ADC Pipeline
Table 53: ImmunoGen’s in-house ADC Pipeline
Table 54: ImmunoGen’s Partnered ADC Programs in Clinical Development
Table 55: Discontinued Clinical Stage ADCs with ImmunoGen Technology
Table 56: Reasons for Failure of TAP-based ADCs Compared with Naked Antibodies
Table 57: Immunomedics‘ Clinical ADC Pipeline
Table 58: Sales of Adcetris
Table 59: Seattle Genetics‘ Adcetris Pipeline of Additional Indications
Table 60: Seattle Genetics‘ in-house ADC Pipeline
Table 61: Seattle Genetics‘ Collaborator ADC Pipeline
Table 62: Discontinued ADCs Based on Technology from Seattle Genetics
Table 63: Stemcentrx‘ Discovered ADC Programs in Clinical Development
Table 64: Centrose‘s EDC Pipeline
Table 65: Mersana’s Proprietary Fleximer ADC Pipeline
Table 66: Sorrento’s Proprietary ADC Pipeline
Table 67: Angiopep’s Oncology Pipeline
Table 68: Endocyte’s Pipeline of Small Molecule Drug Conjugates (SMDCs)

"T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals"

1. Introduction

2. Executive Summary

3. Competitive Landscape Analysis
3.1 Stakeholders
3.1.1 Major biopharmaceutical companies
3.2.2 Small & medium pharmaceutical & biotechnology companies
3.2 Technologies
3.3 Pipeline
3.3.1 Overview
3.3.2 Targets
3.3.3 Competition with other Treatment Modalities
3.3.4 Administration Regimens of T-cell Redirecting Bispecific Antibodies
3.3.5 Next Wave of T-cell and NK-Cell Redirecting Antibodies
3.3.6 Clinical Experience with T-cell and NK-cell redirecting Bispecific Antibodies
3.4 Commercial value of targets, drugs & technologies
3.4.1 Drug prices and sales
3.4.2 Economic terms of collaboration and licensing agreements
3.4.3 Acquisition price (cost) of companies
3.4.4 Public and private financing rounds

4. Company Profiles
4.1 Major Pharma & Biotech
4.1.1 Amgen
4.1.2 AstraZeneca
4.1.3 Bayer
4.1.4 Boehringer Ingelheim
4.1.5 Eli Lilly
4.1.6 GlaxoSmithKline
4.1.7 Janssen Biotech
4.1.8 Pfizer
4.1.9 Roche
4.1.10 Servier
4.2 Small & Medium Pharma & Biotech
4.2.1 Adimab
4.2.2 Affimed Therapeutics
4.2.3 Alligator Biosciences
4.2.4 Ambrx
4.2.5 CytomX
4.2.6 Emergent BioSolutions
4.2.7 EngMab
4.2.8 Eureka Therapeutics
4.2.9 GEMoaB
4.2.10 Generon
4.2.11 Genmab
4.2.12 Glenmark Pharmaceuticals
4.2.13 Immunocore
4.2.14 MacroGenics
4.2.15 Merus
4.2.16 Molecular Partners
4.2.17 Morphosys
4.2.18 Neovii Biotech
4.2.19 OMT Therapeutics
4.2.20 Pieris
4.2.21 Regeneron Pharmaceuticals
4.2.22 Wuhan YZY Biopharma
4.2.23 Xencor
4.2.24 Zymeworks

5. Technology Profiles
5.1 ADAPTIR
5.2 ART-Ig
5.3 Azymetric Scaffold
5.4 BEAT
5.5 Biclonics
5.6 BiTE
5.7 CrossMab
5.8 DART
5.9 Fc-DART
5.10 Dock-and-Lock (DNL)
5.11 DuoBody
5.12 FynomAbs
5.13 ImmTAC
5.14 Knobs-into-Holes
5.15 mAbXcite
5.16 Modified VelocImmune
5.17 TandAb
5.18 T-Cell Engaging Bi-specific (TCB) Probody
5.19 Triomab
5.20 UniDab
5.21 UniTARG/UniMAB
5.22 XmAb Bispecific
5.23 Y-Body Bispecific

6. Drug & Drug Candidate Profiles
6.1 A-337
6.2 AFM11
6.3 AFM13
6.4 AFM21
6.5 AFM22
6.6 AFM24
6.7 AMG 221
6.8 AMG 330
6.9 AMV-564
6.10 BI 836909
6.11 Bispecific anti-CD3-folate
6.12 Blincyto
6.13 CD79b-TDB
6.14 COVA420
6.15 DR5xCD3 DART
6.16 EM801
6.17 EphA2xCD3 DART
6.18 ERY974
6.19 ES414
6.20 ES425
6.21 GBR1302
6.22 GBR1342
6.23 Her2-TDB
6.24 IL13Ra DART
6.25 IMCgp100
6.26 JNJ-63709178
6.27 JNJ-64052781
6.28 M-706
6.29 M-802
6.30 MCLA-117
6.31 MGD006
6.32 MGD007
6.33 MGD009
6.34 MGD014
6.35 Pasotuxizumab
6.36 PF-06671008
6.37 PRS-343
6.38 PSMA-CD3
6.39 REGN1979
6.40 Removab
6.41 RG7802
6.42 RG7828
6.43 ROR1xCD3 DART
6.44 XmAb13551
6.45 XmAb13676
6.46 XmAb14045
6.47 ZW38

7. References

8. Attachment
- Table 16: Clinical Stage T-Cell and NK-Cell Redirecting Bispecific Antibodies
- Table 17: Clinical Combination Studies with T-Cell and NK-Cell Redirecting Bispecific Antibodies
- Table 18: T-Cell and NK-Cell Redirecting Bispecific Antibodies in IND and IND-Enabling Study Phase
- Table 19: T-Cell and NK-Cell Redirecting Bispecific Antibodies in Preclinical R&D

List of Tables

Table 1: Technologies Used by Big Pharma/Biotech in Clinical Stage T-Cell Redirecting Bispecific Antibodies and Compared with Related Technologies
Table 2: T-Cell & NK-Cell Redirecting Bispecific Antibody Technologies from Small & Medium Pharmaceutical Companies and their Licensees
Table 3: Technology Features of Clinical Stage T-Cell & NK-Cell Redirecting Bispecific Antibody Technologies
Table 4: Corporate T-Cell and NK-Cell Redirecting Bispecific Antibody Technologies
Table 5: Targets for T-Cell & NK-Cell Redirecting Bispecific Antibodies
Table 6: Target Competition by Treatment Modalities
Table 7: Technology-Dependent Administration Regimens of Clinical Stage T-Cell & NK-Cell Redirecting Bispecific Antibodies
Table 8: Next Wave of T-Cell and NK-Cell Redirecting Bispecific Antibodies
Table 9: Economic Terms of Licensing Agreements for T-Cell Redirecting Bispecific Antibodies
Table 10: Clinical Development Indications and Status of Blincyto
Table 11: BiTE Development Pipeline by Amgen and/or Partners
Table 12: Affimed’s TandAb Pipeline
Table 13: Goals and Terms of Immunocore’s Partnering Deals for ImmTAC Technology
Table 14: YZY Biopharma‘s Pipeline of T-Cell Redirecting Bispecific Antibodies
Table 15: Clinical Studies with Blincyto (blinatumomab)
Table 16: Clinical Stage T-Cell and NK-Cell Redirecting Bispecific Antibodies
Table 17: Clinical Combination Studies with T-Cell and NK-Cell Redirecting Bispecific Antibodies
Table 18: T-Cell and NK-Cell Redirecting Bispecific Antibodies in IND and IND-Enabling Study Phase
Table 19: T-Cell and NK-Cell Redirecting Bispecific Antibodies in Preclinical R&D

"Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update"

A) 2015 Sales of Therapeutic Antibodies
- Overview: 2015 Biologics Sales per Class of Products
- Overview: 2015 Therapeutic Antibody Sales per Class of Products
- Blockbuster Therapeutic Antibodies in 2015
- Anti-TNF Antibody Sales in 2015
- Cancer Antibody Sales in 2015
- Other Anti-Inflammatory Antibody Sales in 2015
- Ophthalmic Antibody Sales in 2015
- Cardiometabolic & Anti-Infective Antibody Sales in 2015

B) Biosimilar and Biosuperior Anti-TNF Antibodies - 2016 Update

1. Originator Anti-TNF Antibodies
- Approved and Marketed Indications of anti-TNF Antibodies in Regulated Markets
- 2015 Sales of Anti-TNF Antibodies
- Sales of Anti-TNF Antibodies in Q1/2016
- Humira Pipeline of Recently Approved Indications & Upside Developments
- Remicade Pipeline of Recent Approvals & Upside Indications
- Enbrel Pipeline of Upside Indications
- Simponi Pipeline of Recent Approvals & Upside Indications
- Cimzia Pipeline of Recent Approvals & Upside Indications
- Defense Strategies against Biosimilar Anti-TNF Antibodies

2. Biosuperior Anti-TNF Antibodies
- Non-Antibody Anti-TNF Biosuperiors
- Anti-TNF Biosuperior Antibodies

3. Biosimimilar Anti-TNF Antibodies
Humira Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets
Enbrel Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets
Remicade Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Market
Simponi & Cimzia Biosimilar Antibodies

C) Biosimilar and Biosuperior Anti-VEGF/-R Antibodies - 2016 Update

1) Marketed Anti-VEGF/R Products in Oncology
- Avastin, Zaltrap & Cyramza Sales 2008 - 2015
- Avastin Sales and Indication Portfolio
- Zaltrap Sales and Indication Portfolio
- Cyramza Sales and Indication Portfolio

2) Anti-VEGF Biosuperiors of Avastin and Zaltrap
- Anti-VEGF Biosuperior Pipeline in Oncology
- Bispecific Anti-VEGF Pipeline in Oncology

3) Anti-VEGF-R Biosuperiors of Cyramza
- Anti-VEGF-R Biosuperior Pipeline in Oncology
- Bispecific Anti-VEGF-R Pipeline in Oncology

4) Avastin & Cyramza Biosimilar Pipeline in Oncology

5) Marketed Anti-VEGF Products in Ophthalmology
- Lucentis & Eylea Sales 2008 - 2015
- Lucentis Sales & Indication Portfolio
- Eylea Sales & Indication Portfolio

6) Anti-VEGF Biosuperiors of Lucentis and Eylea
- Biosuperior Anti-VEGF in Ophthalmology
- Biosuperior Bispecific Anti-VEGF and Anti-VEGF Combinations in Ophthalmology

7) Other Anti-VEGF Molecules in Ophthalmology

8) Lucentis Biosimilars in Ophthalmology

9) Eylea Biosimilars in Ophthalmology

10) Off-Label Use of Anti-VEGF in Ophthalmology

D) Biosimilar and Biosuperior Anti-Her2 Antibodies - 2016 Update

1. 2015 Anti-Her2 Antibody Sales

2. Originator Anti-Her2 Antibodies
- Herceptin Approved Indications & Pipeline
- Perjeta Approved Indications & Pipeline
- Kadcyla Approved Indications & Pipeline

3. Biosuperior Anti-Her2 Antibodies
- 3rd Generation Anti-Her2 Antibodies
- Bispecific Anti-Her2 Antibodies
- Anti-Her2 Antibody-Drug Conjugates, Immunotoxins, Immunocytokines & Radiopharmaceuticals

4. Biosimilar Anti-Her2 Antibodies
- Herceptin Biosimilar Antibodies
- Developments in Regulated Markets
- Development in Less Regulated Markets

5. Perjeta Biosimilar Antibodies

E) Biosimilar and Biosuperior Anti-CD20 Antibodies - 2016 Update

1. 2015 Sales of Anti-CD20 Antibodies

2. Originator Anti-CD20 Antibodies
- Rituxan / MabThera Approved Indications & Pipeline
- Gazyva Approved Indications & Pipeline
- Arzerra Approved Indications and R&D Pipeline
- Zevalin Approved Indications

3. Biosuperior Anti-CD20 Antibodies
- 3rd Generation Anti-CD20 Antibodies
- Bispecific Anti-CD20 Antibodies
- Anti-CD20 Antibody-Drug Conjugates, Immunotoxins & Immunocytokines

4. Biosimilar Anti-CD20 Antibodies
Rituxan/MabThera Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets

5. Arzerra Biosimilar Antibodies

F) Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

1. Sales of Anti-EGF-R Antibodies

2. Originator Anti-EGF-R Antibodies
- Erbitux Approved Indications & Pipeline
- Vectibix Approved Indications & Pipeline
- Nimotuzumab Approved Indications & Pipeline
- Portrazza Approved Indications & Pipeline

3. Biosuperior Anti-EGF-R Antibodies
- 3rd Generation Anti-EGF-R Antibodies
- Bispecific Anti-EGF-R Antibodies
- Anti-EGF-R Antibody Drug Conjugates

4. Biosimilar Anti-EGF-R Antibodies
Erbitux Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets

G) Next Wave of Biosimilar Antibodies - 2016 Update
- Abatacept Biosimilar Antibodies
- Aletuzumab Biosimilar Antibodies
- Denosumab Biosimilar Antibodies
- Eculizumab Biosimilar Antibodies
- Omalizumab Biosimilar Antibodies
- Palivizumab Biosimilar Antibodies
- Tocilizumab Biosimilar Antibodies
- Ustekinumab Biosimilar Antibodies
- Biosimilars of Immune Checkpoint Inhibitor Antibodies

H) Corporate Biosimilar & Biosuperior Therapeutic Antibody Pipelines

"Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases"

1. Bispecific Antibodies for Cancer, Inflammatory & Other Diseases
- T-Cell Redirecting Bispecific Cancer Antibodies
- NK Cell Redirecting Bispecific Cancer Antibodies
- Bispecific Immuno-Oncology Antibodies
- Bispecific Tumor Antigens Targeted Cancer Antibodies
- Bispecific Antibodies for Inflammatory & Autoimmune Diseases
- Bispecific Antibodies Outside Oncology & Inflammation
- Antibody Cocktails & Oligo- and Polyclonal Antibodies

2. Corporate Bispecific Antibody Pipelines
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
"Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis"

- 3SBio
- ACES Pharma
- ADC Therapeutics
- APO-T
- AbbVie
- Ablynx
- Affilogic
- Affitech
- Alethia Biotherapeutics
- Alteogen
- Ambrx
- Amgen
- Angiochem
- Antikor Biopharma
- Asana Biosciences
- Astellas Pharma
- AstraZeneca
- BIND Therapeutics
- Bayer HealthCare Pharmaceuticals
- Bicycle Therapeutics
- Biotest
- Blend Therapeutics
- Bristol-Myers Sqibb
- Catalent Pharma Solutions (Redwood Bioscience)
- Celgene
- Celldex Pharmaceuticals
- Centrose
- CureMeta
- CytRx
- CytomX Therapeutics
- Daiichi Sankyo
- Delenex Therapeutics
- Dophen Biomed
- Eisai
- Eli Lilly
- Endocyte
- Formation Biologics
- Fosun Pharma
- Genmab
- GlaxoSmithKline
- Glycotope
- Hanwha Chemical
- Heidelberg Pharma
- Helix BioPharma
- Igenica Biotherapeutics
- Immune Pharmaceuticals
- ImmunoGen
- Immunomedics
- Innate Pharma
- Janssen (Johnson & Johnson)
- Kairos Therapeutics
- LegoChem Biosciences
- LinXis
- Meditope Biosciences
- Menarini
- Merck Serono
- Merrimack Pharmaceuticals
- Mersana Therapeutics
- Mistubishi Tanabe Pharma
- MultiCell Immunotherapeutics
- NBE Therapeutics
- NanoCarrier
- Nerviano Medical Sciences
- Novartis
- OntoChem
- Oxford BioTherapeutics
- Oxis Biotech
- Pfizer
- Pharmamar
- Philogen
- Polytherics (Abzena)
- Progenics Pharmaceuticals
- Quanta Biodesign
- Regeneron Pharmaceuticals
- Roche
- Sanofi
- Scil Proteins
- Seattle Genetics
- Serina Therapeutics
- Sorrento Therapeutics (Concortis Biosystems)
- Stemcentrx
- Sutro Biopharma
- SynAffix
- Synta Pharmaceuticals
- Synthon Biopharmaceuticals
- Takeda Pharmaceutical Co
- WuXi PharmaTech
- Zhejiang Medicine Co.
- Zova Biotherapeutics
- Zymeworks

"T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals"

- Adimab
- Affimed Therapeutics
- Alligator Biosciences
- Ambrx
- Amgen
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- CytomX
- Eli Lilly
- Emergent BioSolutions
- EngMab
- Eureka Therapeutics
- GEMoaB
- Generon
- Genmab
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- ImmuneXcite
- Immunocore
- Immunomedics
- Janssen Biotech
- MacroGenics
- Merus
- Molecular Partners
- Morphosys
- Neovii Biotech
- OMT Therapeutics
- Pfizer
- Pieris Pharmaceuticals
- Regeneron Pharmaceuticals
- Roche
- Servier
- Wuhan YZY Biopharma
- Xencor
- Zymeworks

"Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update"

- 3SBio (Shenyang Sunshine Pharmaceutical Co)
- AET Biotech
- AREVA Med
- AVEO Pharmaceuticals
- AbClon
- AbbVie
- Ablynx
- Affibody
- Affilogic
- Affimed Therapeutics
- Affitech
- Allergan
- Alopexx Oncology
- Alteogen
- Alvogen
- Ambrx
- Amega Biotech
- Amgen
- AngioChem
- Apexigen
- Aprogen
- Archemix
- Aryogen
- Ascendis Pharma
- AstraZeneca (MedImmune)
- Avaxia Biologics
- Axxo
- Baliopharm
- Baxalta
- Bayer
- biOasis Technologies
- Binex
- Bio Farma
- BioCND
- BioXpress Therapeutics
- Biocad
- Biocon
- Bioeq
- Biogen
- Bionovis
- Boehringer Ingelheim
- Bristol-Myers Squibb
- CIMAB
- Celgene
- Celltrion
- Centrose
- Ceres Oncology
- Chengdu Kanghong Biotech Co.
- Cipla
- Clearside Biomedical
- Coherus Biosciences
- Complix
- Cristalia
- Curaxys
- CytomX Therapeutics
- Daewoong Pharmaceutical Co
- Daiichi Sankyo
- Delenex Therapeutics
- Dermira
- Dong-A ST
- Dr Reddy’s Laboratories
- Eddingpharma
- Eisai
- Eli Lilly
- EnGenlC
- Epirus Biopharmaceuticals
- Esperance Pharmaceuticals
- Exicure
- Ferring Pharmaceuticals
- ForSight VISION4
- Fosun Pharma
- Fujifilm Kyowa Kirin Biologics
- Gansu Duyiwei Biological Pharmaceutical Co
- Gedeon Richter
- GenIlac
- Gene Techno Science (GTS)
- Genor Biopharma
- Glenmark Pharmaceuticals
- Gliknik
- Glycotope
- Green Cross
- Halozyme
- HanAll Pharmaceuticals
- Hanwha Chemical Biologics Business
- Harvest Moon Pharmaceuticals
- Helvetic BioPharma
- Hetero Group
- Hyprocell
- IBC Generium
- Ildong Pharmaceutical
- Immune Pharmaceuticals
- ImmuneXcite
- Immunomedics
- Innogene Kalbiotech
- Innokeys
- Innovent Biologics
- Intas Pharmaceuticals
- JHL Biotech
- Janssen (Johnson & Johnson)
- Jiangsu Simcere Pharmaceutical
- Jiangsu T-mab Biopharma
- Kissei Pharmaceutical
- Kyowa Hakko Kirin
- LG Life Sciences
- LegoChem
- Libbs Farmaceutica
- MabTech
- MabXience
- Mabion
- MacroGenics
- Meiji Seika
- Merck (MSD)
- Merck Biopharma & HealthCare Biosimilars
- Merrimack Pharmaceuticals
- Mersana Therapeutics
- Merus
- Mitsubishi Tanabe Pharma
- Mochida
- Molecular Partners
- Molecular Templates
- Momenta Pharmaceuticals
- Mundipharm
- Mycenax Biotech
- Mylan Pharmaceuticals
- Nanogen Biopharmaceutical Co
- Natco Pharma
- Neurotech
- Nichi-iko Pharmaceutical
- Nippon Kayaku
- Novartis (& Sandoz/Alcon)
- OncoMed Pharmaceuticals
- Oncobiologics
- Ophthea
- Ophthotech
- Orygen Biotecnologia
- PanOptica
- Paras Biopharmaceuticals
- Pfenex
- Pfizer (& Hospira)
- PharmAbcine
- Pharmamar
- Pharmapraxis
- Pieris Pharmaceuticals
- PlantForm
- Polpharma Group
- Probiomed
- Protalix Biotherapeutics
- Ranbaxy
- Regeneron Pharmaceuticals
- Reliance Life Sciences
- Roche
- STC Biologics
- Samsung Bioepis (JV of Samsung and Biogen)
- Sanofi
- Senju Pharmaceutical
- Shanghai Biomabs Pharmaceutical
- Shanghai Celgen BioPharmaceutical Co
- Shanghai Citi Pacific (CO) Guojian Pharmaceutical Co (CPGP)
- Shanghai Fudan-Zhangjiang BioPharmaceuticals
- Shanghai Henlius Biotech
- Shanghai Zhangjiang Biotechnology (ZJ-Bio)
- Sirnaomics
- Sorrento Biologics/Therapeutics
- Spectrum Pharmaceuticals
- Stada Arzneimittel
- Syd labs
- Symphogen
- Synthon Biopharmaceuticals
- TG Therapeutics
- TPG Biologics
- TSH Pharma
- Taisho Pharmaceutical
- Takeda Pharmaceutical Co
- Therapeutics Protein International (TPI)
- Tillots Pharma
- Torrent Pharma
- Trimer Biotech
- Triphase Accelerator
- Tyrogenex
- UCB
- Unum Therapeutics
- Vaccinex
- Valeant Pharmaceuticals
- Valor Biotherapeutics
- Wuhan YZY Biopharma
- Xbrane Biopharma
- Xencor
- YL Biologics
- Yuhan
- Zhejiang Huahai Pharmaceutical Co
- Zhejiang Medicine
- Zova Biotherapeutics
- Zydus Cadila
- Zymeworks
- Zyngenia
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll